Nov11,2020:Russia’s Sputnik V vaccine has proven to be “92% efficacious” among a group of volunteers who are part of Phase 3 trials to test the vaccine, the Russian Health Ministry said in a statement on Wednesday.
The results were based on an analysis of 20 participants in the trial who were confirmed COVID-19 positive. The trials consists of 20,000 people who got one dose of the vaccine, and 16,000 who got two, 14 days apart. The efficacy percentage means that when cases were split among the placebo group and vaccinated group, 92% of those who were vaccinated were safe.
This is close to the efficacy percentage claimed by Pfizer on Monday that said its RNA vaccine was 90% efficacious, though that relied on a larger COVID-19-positive volunteer set of 94.
The Russian trials are ongoing in multiple countries, and a Phase 2/3 trial that tests for a immune reaction in a limited number of people is ongoing in India too. Hyderabad-based Dr. Reddy’s Laboratories is a partner of the Russian organisation, Gamaleya Research Foundation, that has developed Sputnik V.
